Dirucotide Fails To Meet Primary Endpoint

BioMS Medical and Eli Lilly have reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS). The result was obtained during the two-year phase III trial in patients with secondary progressive multiple sclerosis (SPMS).

In addition to that, there were no significant differences between dirucotide and placebo on the secondary endpoints of the study.

Lilly and BioMS have also reported that they would discontinue ongoing clinical trials and review available data.

Robert Bishop, CEO of AutoImmune, said: We are obviously disappointed by the results and look forward to further announcements from BioMS and Lilly regarding their future plans for this approach to treating SPMS.